Pfanstiehl Laboratories

Pfanstiehl Laboratories specializes in high-purity injectable grade excipients crucial for biopharmaceuticals and vaccines, ensuring safety and stability in formulations. Pfanstiehl Laboratories develops high-purity injectable excipients designed to support biopharmaceutical and vaccine production. The company was acquired by Med Opportunity Partners in April 2013 for USD 24. 9 mn, marking a significant pivot in its operational strategy.

Headquartered in Waukegan, US, Pfanstiehl operates with a focus on compliance and quality. The CEO, James Breckenridge, brings a wealth of experience in the industry. Pfanstiehl specializes in high-purity, low-endotoxin, and low-metal injectable grade excipients, branded as HPLE-LM™. These excipients are critical for the safety and stability of biopharmaceuticals and vaccines, addressing challenges like protein aggregation and viscosity in high-concentration formulations.

Their product range supports vaccine and biologic stabilization, polysorbate degradation mitigation, and complex chemistry applications, catering to biopharmaceutical manufacturers and vaccine producers in North America, Europe, and Asia. Compliance with GMP standards underpins their manufacturing practices, ensuring product quality. Pfanstiehl's revenue model is centered on B2B transactions with biopharmaceutical companies and vaccine manufacturers, involving bulk orders of HPLE-LM™ injectable excipients tailored to customer specifications. Clients may engage in long-term contracts for a steady supply, contributing to a stable revenue stream.

The company also offers custom manufacturing solutions, enhancing revenue through bespoke services that meet specific client needs. Looking ahead, Pfanstiehl intends to leverage the USD 24. 9 mn acquired in April 2013 to enhance its product offerings and expand into new markets. The company is currently designing additional products to address emerging needs in biologic therapies, with a focus on launching these innovations by the end of 2024.

Expansion plans also include targeting new markets in Asia and Europe to broaden its client base by 2025.